Does understanding endotypes translate to better asthma management options for all?

Area of Science:

• Pulmonology
• Precision Medicine
• Biomarker Discovery

Background:

• Despite advances in asthma therapies and delivery systems, the disease burden persists.
• Predicting individual patient responses to asthma medications and achieving personalized treatment remain significant challenges.
• Current asthma management often employs a generalized, symptom-based approach, failing to account for disease heterogeneity.

Purpose of the Study:

• To highlight the limitations of the current reductionist view of asthma as a single disease.
• To advocate for a shift towards an endotype-based, stratified approach to asthma care.
• To propose a methodology for discovering asthma endotypes, biomarkers, and personalized treatments.

Main Methods:

• Analyzing big data from birth and patient cohorts.
• Interpreting treatment responses from randomized controlled trials.
• Conducting in vitro mechanistic studies using human samples and animal models.

Main Results:

• Current asthma management strategies are often ineffective due to treating diverse subtypes as a single entity.
• Biomarkers like allergic sensitization and blood eosinophilia are underutilized in predicting corticosteroid response.
• The lack of endotype identification hinders the development of personalized asthma therapies.

Conclusions:

• A stratified, endotype-driven approach is essential for advancing asthma treatment and achieving personalized medicine.
• An iterative research process integrating big data, clinical trial outcomes, and mechanistic studies is proposed for endotype discovery.
• Understanding asthma endotypes is key to developing targeted therapies and ultimately finding a cure.